Insulin therapy of type 2 diabetes mellitus

Main Article Content

G.F. Gendeleka
A.N. Gendeleka

Abstract

Basal insulin therapy in combination with oral hypoglycemic drugs has a special effect on fasting blood glucose. It is a simple way of introducing insulin therapy in patients with type 2 diabetes mellitus subjected to further prandial insulin therapy. Treatment with insulin mixtures reduces both fasting blood glucose and postprandial blood sugar, which has a negative effect on the development of vascular complications. With this simple therapy, there are limitations in everyday life and an adverse effect on the dynamics of body weight. Basal-bolus therapy focuses on pathophysiological changes, and with professional training and high-quality self-control provides good results with sufficient flexibility in everyday life. All insulin analogues have advantages over human insulins in terms of treatment outcomes, safety and patient compliance. All types of insulin therapy in clinical practice can be carried out by simple schemes

Article Details

How to Cite
Gendeleka, G., and A. Gendeleka. “Insulin Therapy of Type 2 Diabetes Mellitus”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 16, no. 1, Feb. 2020, pp. 63-68, doi:10.22141/2224-0721.16.1.2020.199130.
Section
Literature Review

References

Sokolova LK. Insulin therapy for patients with diabetes mellitus. When? To whom? For what purpose? Available from: http://www.iem.net.ua/for-specialists/publications/?view=124. (in Ukrainian).

von Bibra H, Siegmund T, Kingreen I, Riemer M, Schuster T, Schumm-Draeger PM. Effects of analogue insulin in multiple daily injection therapy of type 2 diabetes on postprandial glucose control and cardiac function compared to human insulin: a randomized controlled long-term study. Cardiovasc Diabetol. 2016;15:7. doi:10.1186/s12933-015-0320-2.

Lovre D, Fonseca V. Benefits of timely basal insulin control in patients with type 2 diabetes. J Diabetes Complications. 2015;29(2):295–301. doi:10.1016/j.jdiacomp.2014.11.018.

Meah F, Juneja R. Insulin tactics in type 2 diabetes. Med Clin North Am. 2015;99(1):157–186. doi:10.1016/j.mcna.2014.08.021.

Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361(18):1736–1747. doi:10.1056/NEJMoa0905479.

McBrien KA, Manns BJ, Chui B, et al. Health care costs in people with diabetes and their association with glycemic control and kidney function. Diabetes Care. 2013;36(5):1172–1180. doi:10.2337/dc12-0862.

Freemantle N, Danchin N, Calvi-Gries F, Vincent M, Home PD. Relationship of glycaemic control and hypoglycaemic episodes to 4-year cardiovascular outcomes in people with type 2 diabetes starting insulin. Diabetes Obes Metab. 2016;18(2):152–158. doi:10.1111/dom.12598.

Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of endocrinology on the comprehensive type 2 diabetes management algorithm – 2017 executive summary. Endocr Pract. 2017;23(2):207–238. doi:10.4158/EP161682.CS.

Gerstein HC, Ferrannini E, Riddle MC, Yusuf S; ORIGIN Trial Investigators. Insulin resistance and cardiovascular outcomes in the ORIGIN trial. Diabetes Obes Metab. 2018;20(3):564–570. doi:10.1111/dom.13112.

Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections: A Randomized Trial. Ann Intern Med. 2017;167(6):365–374. doi:10.7326/M16-2855.

Riddle MC, Bolli GB, Ziemen M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care. 2014;37(10):2755–2762. doi:10.2337/dc14-0991.

Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357(17):1716–1730. doi:10.1056/NEJMoa075392. 

Buse JB, Wolffenbuttel BH, Herman WH, et al. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care. 2009;32(6):1007–1013. doi:10.2337/dc08-2117.

Strange P. Treat-to-target insulin titration algorithms when initiating long or intermediate acting insulin in type 2 diabetes. J Diabetes Sci Technol. 2007;1(4):540–548. doi:10.1177/193229680700100412.

Harper R, Donnelly R, Bi Y, Bashan E, Minhas R, Hodish I. Dynamics in insulin requirements and treatment safety. J Diabetes Complications. 2016;30(7):1333–1338. doi:10.1016/j.jdiacomp.2016.05.017.

Hodish I. Can the current healthcare delivery model cope with advanced type 2 diabetes? J Diabetes Complications. 2015;29(3):321–322. doi:10.1016/j.jdiacomp.2015.01.005.

Hayward RA, Reaven PD, Emanuele NV; VADT Investigators. Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015;373(10):978. doi:10.1056/NEJMc1508386.

Ganz ML, Wintfeld NS, Li Q, Lee YC, Gatt E, Huang JC. Severe hypoglycemia rates and associated costs among type 2 diabetics starting basal insulin therapy in the United States. Curr Med Res Opin. 2014;30(10):1991–2000. doi:10.1185/03007995.2014.936930.

Gamble JM, Chibrikov E, Twells LK, et al. Association of insulin dosage with mortality or major adverse cardiovascular events: a retrospective cohort study. Lancet Diabetes Endocrinol. 2017;5(1):43–52. doi:10.1016/S2213-8587(16)30316-3.

Mora P, Buskirk A, Lyden M, Parkin CG, Borsa L, Petersen B. Use of a Novel, Remotely Connected Diabetes Management System Is Associated with Increased Treatment Satisfaction, Reduced Diabetes Distress, and Improved Glycemic Control in Individuals with Insulin-Treated Diabetes: First Results from the Personal Diabetes Management Study. Diabetes Technol Ther. 2017;19(12):715–722. doi:10.1089/dia.2017.0206.